liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using In Vitro Models Derived from Human Embryonic Stem Cells and Human Cell Lines - A Report on the Vitrocellomics EU-project
Linköping University, Department of Physics, Chemistry and Biology, Biotechnology . Linköping University, The Institute of Technology.
Department of Physiology and Pharmacology, Karolinska Institute, Stockholm.
IBET, Oeiras, Portugal .
Pharmacelsus GmbH, Saarbrücken, Germany.
Show others and affiliations
2011 (English)In: ATLA-ALTERNATIVES TO LABORATORY ANIMALS, ISSN 0261-1929, Vol. 39, no 2, 147-171 p.Article in journal (Refereed) Published
Abstract [en]

Drug-induced liver injury is a common reason for drug attrition in late clinical phases, and even for post-launch withdrawals. As a consequence, there is a broad consensus in the pharmaceutical industry, and within regulatory authorities, that a significant improvement of the current in vitro test methodologies for accurate assessment and prediction of such adverse effects is needed. For this purpose, appropriate in vivo-like hepatic in vitro models are necessary, in addition to novel sources of human hepatocytes. In this report, we describe recent and ongoing research toward the use of human embryonic stem cell (hESC)-derived hepatic cells, in conjunction with new and improved test methods, for evaluating drug metabolism and hepatotoxicity. Recent progress on the directed differentiation of human embryonic stem cells to the functional hepatic phenotype is reported, as well as the development and adaptation of bioreactors and toxicity assay technologies for the testing of hepatic cells. The aim of achieving a testing platform for metabolism and hepatotoxicity assessment, based on hESC-derived hepatic cells, has advanced markedly in the last 2-3 years. However, great challenges still remain, before such new test systems could be routinely used by the industry. In particular, we give an overview of results from the Vitrocellomics project (EU Framework 6) and discuss these in relation to the current state-of-the-art and the remaining difficulties, with suggestions on how to proceed before such in vitro systems can be implemented in industrial discovery and development settings and in regulatory acceptance.

Place, publisher, year, edition, pages
Fund for Replacement of Animals in Medical Experiments; 1999 , 2011. Vol. 39, no 2, 147-171 p.
Keyword [en]
3-D microstructures, ADMET, artificial liver devices, bioreactors, biosensors, human embryonic stem cells, in vitro toxicity testing, induction assay, metabolic flux analysis, respiratory assay
National Category
Engineering and Technology
URN: urn:nbn:se:liu:diva-69184ISI: 000291181500020OAI: diva2:424296
Available from: 2011-06-17 Created: 2011-06-17 Last updated: 2011-06-30

Open Access in DiVA

No full text

Search in DiVA

By author/editor
Mandenius, Carl-FredrikFredriksson, J. Magnus
By organisation
Biotechnology The Institute of Technology
Engineering and Technology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 138 hits
ReferencesLink to record
Permanent link

Direct link